Paysign (PAYS) Projected to Announce Earnings on Monday

Paysign (NASDAQ:PAYS) is projected to post its Q3 2026 results after the market closes on Monday, November 9th. Analysts expect the company to post earnings of $0.09 per share and revenue of $29.02 million for the quarter. Paysign has set its FY 2026 guidance at 0.350-0.370 EPS and its Q3 2026 guidance at 0.090-0.100 EPS. Individuals can check the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Monday, November 9, 2026 at 5:00 PM ET.

Paysign (NASDAQ:PAYS) last posted its earnings results on Wednesday, August 5th. The company reported $0.11 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.05. Paysign had a net margin of 15.67% and a return on equity of 30.13%. The firm had revenue of $28.25 million for the quarter, compared to analysts’ expectations of $26.36 million. On average, analysts expect Paysign to post $0.58 EPS for the current fiscal year and $0.71 EPS for the next fiscal year.

Paysign Trading Up 4.6%

PAYS traded up $0.64 during trading on Monday, reaching $14.57. 135,370 shares of the company’s stock were exchanged, compared to its average volume of 720,823. Paysign has a one year low of $3.08 and a one year high of $16.15. The stock has a market capitalization of $822.65 million, a PE ratio of 55.83 and a beta of 0.83. The firm has a fifty day moving average price of $13.77 and a two-hundred day moving average price of $8.31.

Insider Buying and Selling at Paysign

In related news, EVP Joan Herman sold 38,900 shares of the firm’s stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $11.74, for a total value of $456,686.00. Following the transaction, the executive vice president owned 609,421 shares of the company’s stock, valued at approximately $7,154,602.54. This trade represents a 6.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Michael Ngo sold 79,925 shares of the business’s stock in a transaction that occurred on Wednesday, September 9th. The stock was sold at an average price of $12.74, for a total value of $1,018,244.50. Following the sale, the insider directly owned 2,350,000 shares of the company’s stock, valued at $29,939,000. This represents a 3.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 444,904 shares of company stock valued at $5,626,124. Insiders own 24.50% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on PAYS. DA Davidson increased their price target on Paysign from $12.00 to $15.00 and gave the stock a “buy” rating in a report on Wednesday, September 30th. Wall Street Zen downgraded shares of Paysign from a “strong-buy” rating to a “buy” rating in a research report on Sunday, August 16th. Barrington Research set a $15.00 price target on shares of Paysign in a report on Tuesday, August 11th. Lake Street Capital upped their price objective on shares of Paysign from $13.00 to $15.00 and gave the company a “buy” rating in a report on Tuesday, September 15th. Finally, Weiss Ratings raised shares of Paysign from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, October 8th. Three equities research analysts have rated the stock with a Buy rating. According to MarketBeat.com, Paysign has a consensus rating of “Buy” and an average target price of $15.00.

About Paysign

Paysign, Inc (NASDAQ: PAYS) is a financial technology company that provides payment and prepaid card solutions for businesses and organizations. Its platform supports the issuance, distribution and management of branded prepaid cards and other electronic payment products, helping clients deliver funds to consumers and program participants.

The company serves several specialized markets, including plasma collection centers, pharmaceutical manufacturers and other healthcare-related organizations.